<DOC>
	<DOCNO>NCT01019395</DOCNO>
	<brief_summary>This research study design look pharmacokinetics ( distribution , breakdown , removal ) tolerability single dose daptomycin patient age 3 month 24 month proven suspect infection cause specific group bacteria ( call Gram-positive bacteria ) perioperative subject receive prophylactic antibiotic .</brief_summary>
	<brief_title>Pharmacokinetics ( PK ) Safety Evaluation Daptomycin Children Ages 3-24 Months With Proven Suspected Gram-positive Infections Peri-Operative Subjects Receiving Prophylactic Antibiotics</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Positive Bacterial Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Written parental ( appropriate legal representative ) inform consent prior studyrelated procedure part normal medical care ; 2.1 Male female age 3 month 24 month , inclusive ; 3 . Able comply protocol duration study ; 4.1 Clinically stable evidence hemodynamic instability ( defined requirement inotropic vasodilatory support manage blood pressure ) 24 hour window prior first dose , history evidence renal hepatic compromise ; 5.1 Suspected diagnose bacterial infection subject receive standard antibiotic therapy ; include prophylactic use antibiotic perioperatively ; 6 . A calculated creatinine clearance rate ( CLcr ) â‰¥ 80 ml/min/1.73m2 determine Schwartz equation baseline ; 7 . Creatine phosphokinase ( CPK ) level less 2X ULN ( upper limit normal ) baseline ; 8.1 Presence two patent intravenous line ( comparable mean venous arterial access ) prior dose Study Day 1 . A single intravenous line ( comparable mean venous access ) acceptable drug administration sample collection reasonable effort gain second line unsuccessful . The line must flush described Appendix B protocol prior obtain PK sample . PK sample obtain perioperatively place arterial line . Arterial PK sample indicate CRF . 1 . Investigational drug use ( include daptomycin ) participation experimental procedure 30 day precede study entry ; 2 . Known allergy/ hypersensitivity daptomycin ; 3.1 History clinically significant , renal , hepatic , autoimmune disease primary immune deficiency ; 4 . Deleted 5 . Subjects clinically significant abnormal laboratory test result ( include ECGs ) , determine Investigator ; 6 . Administration rifampin within 7 day study drug administration ; 7 . Deleted 8 . Subjects collection require blood volume would put risk hemodynamic disturbance ( discretion Investigator ) ; 9 . Deleted ; 10.1 Planned administration intramuscular injection within 12 hour follow study administration unless approve Medical Monitor ; 11 . Deleted 12.1 GuillianBarre spinal cord injury ; 13 . History current rhabdomyolysis .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Gram Positive Infection</keyword>
	<keyword>Concurrent Antibiotic Treatment</keyword>
</DOC>